A Study to Evaluate the Safety, Immunologic, and Virologic RESponses of Donor Derived (DD) HIV-Specific T-cells (HST) With Non-escaped Epitope Targeting (NEETs) in HIV-Infected Individuals on Antiretroviral Therapy Following Allogeneic Bone Marrow Transplantation (alloRESIST)
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 8
- 试验地点
- 2
- 主要终点
- Any ≥ Grade 3 Adverse Events (as defined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0)
研究概览
简要总结
This is a multi-site phase 1 study of the safety, immunologic and virologic responses of ex vivo expanded donor-derived (DD) HIV-1 multi-antigen specific T-cell (HST) with non-escaped epitope targeting (NEET) therapy as a therapeutic strategy in HIV-infected individuals following Allogeneic Bone Marrow Transplantation (alloBMT).
详细描述
The primary objective of this study is to evaluate the safety of donor-derived allogeneic expanded HIV-specific T-cell therapy (DD HST-NEETs) in HIV-infected alloBMT recipients on ART. Eligible donors will undergo a blood draw of up to 300mL to allow production of allogeneic DD HST-NEETs. Participants who meet specified inclusion criteria including neutrophil recovery post-transplant and for whom donor products have passed release testing will receive DD HST-NEETs at a dose of 2x107/m2 within 30 days of screening visit.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participant Inclusion Criteria at Screening:
- •Age ≥18 years.
- •Confirmation of HIV-1 infection. Any licensed ELISA test kit which is confirmed by Western blot or Multispot HIV-1/HIV-2 assay prior to screening. HIV culture, HIV antigen, plasma HIV RNA, or a second antibody test by a method other than ELISA is acceptable as an alternative confirmatory test.
- •On effective antiretroviral therapy.
- •Ability and willingness of participant to continue and be compliant with ART throughout the study.
- •Hematologic malignancy that qualifies for standard of care alloBMT according to JHU criteria.
- •Potential participant must have adequate organ function for standard of care alloBMT according to JHU criteria.
- •No active HCV infection. (If seropositive, participant must have no measureable HCV RNA within 30 days of enrollment).
- •No active HBV infection (If seropositive, participant must have no measureable HBV DNA or HBsAg+ within 30 days of enrollment).
- •Ability and willingness of participant to give written informed consent.
- •Ability and willingness to communicate effectively with study personnel; considered reliable, willing, and cooperative in terms of compliance with the Protocol requirements.
- •Ability and willingness to provide adequate locator information and contact information for at least 2 adults who can reach the participant within 24 hours
- •Participant Inclusion Criteria for DD HST-NEETs Infusion:
- •Karnofsky score of ≥
- •ANC ≥ 250/µL.
- •Bilirubin ≤ 2x upper limit normal or direct bilirubin normal.
- •AST ≤ 3x upper limit normal.
- •Serum creatinine ≤ 2x upper limit normal.
- •Hgb ≥ 7.0 g/dL.
- •Pulse oximetry of > 90% on room air.
- •Negative pregnancy test in female participants if applicable (childbearing potential).
- •Written informed consent signed by participant or guardian.
- •Steroids less or equal to 0.5 mg/kg/day prednisone.
- •Donor Inclusion Criteria for Procurement for DD HST-NEETS Manufacturing:
- •Donors for allogeneic (i.e. HLA matched or mismatched related or unrelated) hematopoietic cell transplants who have fulfilled eligibility for and consented to stem cell donation as per JHU standard operating procedures.
- •Donor must be in good health based on institutional guidelines.
- •Female donors of childbearing age must have a negative pregnancy test and must not be lactating.
- •It is understood that medical clearance from the donor will be sought within the timeline per the National Marrow Donor Program (NMDP) rules.
- •The hematopoietic cell donor will have already been selected by the JHU BMT Donor Selection Committee.
- •Donor or parent/guardian capable of providing informed consent
排除标准
- •Participant Exclusion Criteria DD HST-NEETs Infusion:
- •Participants receiving ATG, or Campath or other immunosuppressive T-cell monoclonal antibodies within 28 days.
- •Participants with uncontrolled infections. For bacterial infections, participants must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to enrollment. For fungal infections participants must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to enrollment. Progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection.
- •Participants who have received donor lymphocyte infusion (DLI) within 28 days.
- •Active and uncontrolled relapse of malignancy.
- •Participants with active acute GVHD grades II-IV
- •Participants with bronchiolitis obliterans syndrome or serositis
- •Any licensed or experimental non-HIV vaccination (e.g., hepatitis B, pneumococcal polysaccharide) within 28 days prior to study entry.
- •Inability to comply with study requirements, which could impact study integrity and/or safety.
- •Donor Exclusion Criteria for Procurement for DD HST-NEETs Manufacturing:
- •Donor exclusion criteria will be followed as per institution standard operating procedures (SOPs).
研究组 & 干预措施
Donor Derived HIV-Specific T-cells (DD HST-NEETs)
Participants who meet specified inclusion criteria including neutrophil recovery post-transplant and for whom donor products have passed release testing will receive DD HST-NEETs at a dose of 2x107/m2 within 30 days of screening visit.
干预措施: DD HST-NEETs (Biological)
结局指标
主要结局
Any ≥ Grade 3 Adverse Events (as defined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0)
时间窗: 45 days
Any ≥ Grade 3 Adverse Events will be measured by number of participants who experience Dose Limiting Toxicity which is attributable to the DD HST-NEETS administration.
次要结局
- The feasibility of manufacturing of DD HST-NEETs(3 years)
- The HIV reservoir measurements(3 years)
研究者
Catherine Bollard
Director, Center for Cancer and Immunology Research
Children's National Research Institute